Why Sellas Life Sciences Stock Rose over 11% Today
Today, Sellas Life Sciences (SLS) announced that the FDA has assigned fast-track designation to its lead drug, GPS (galinpepimut-S), which is under development for the treatment of multiple myeloma. On the news, SLS stock spiked more than 11% today.